Portfolio Company Certa Therapeutics granted US FDA fast track designation for candidate drug FT011

Fantastic news for portfolio company Certa Therapeutics. The FDA has granted Fast Track designation for their candidate drug FT011, an oral therapy for the treatment of Scleroderma, expediting their pathway to market.

This comes following the release of positive Phase 2 trial data, where FT011 demonstrated a clinically significant improvement in 60% of Scleroderma patients following 12 weeks of treatment.

Congratulations to the team on achieving another significant milestone!

To learn more on this update, read the full announcement here